TPP-9476  (Synonyms: BAY-943 antibody)

TPP-9476 is an anti-human IL3RA (CD123) monoclonal antibody with human IL3RA K_d of 11 nM and cynomolgus monkey IL3RA K_d of 16 nM. TPP-9476 binds specifically to human and cynomolgus monkey IL3RA, undergoes target-dependent internalization into lysosomes of IL3RA-positive cells.TPP-9476 exerts antiproliferative effects in IL3RA-expressing acute myeloid leukemia and classical Hodgkin lymphoma cells, reduces tumor burden, improves survival, and induces complete tumor remission in relevant xenograft mouse models^[1].

Human

TPP-9476 (IL3RA-targeting antibody) (titrated log M values) binds with high affinity to recombinant human and cynomolgus monkey IL3RA protein, and shows specific, dose-dependent binding to IL3RA-positive human acute myeloid leukemia cell lines MV-4-11, MOLM-13, and KG-1, with no binding to murine IL3RA^[1].
TPP-9476 (IL3RA-targeting antibody) (10-20 μg/mL; 0-6 h) undergoes specific, time-dependent internalization into IL3RA-positive MOLM-13 and MV-4-11 acute myeloid leukemia cells, and colocalizes with lysosomes in MOLM-13 cells but not IL3RA-negative HBL-1 cells^[1].
TPP-9476 (IL3RA-targeting antibody) (up to 3.00 × 10^-7 M; 72 h) alone has no antiproliferative activity in IL3RA-positive human acute myeloid leukemia and Hodgkin lymphoma cell lines, even at concentrations up to 3.00 × 10^-7 M after 72 h incubation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

TPP-9476 (5 mg/kg, once every 7 days, twice) shows no tumor growth inhibition in the MV-4-11 model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3563  [NCBI]

P26951

IL-3Ra/CD123

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

[TPP-9476]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kirchhoff D, et al. IL3RA-Targeting Antibody-Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies. Cancers (Basel). 2020;12(11):3464. Published 2020 Nov 20.  [Content Brief]